Tyler Patchen

Gen­mab and Seagen’s cer­vi­cal can­cer drug Tiv­dak has reached its pri­ma­ry end­point in a con­fir­ma­to­ry Phase III tri­al, and the re­sults are ex­pect­ed to sup­port

GSK is in­vest­ing about $270 mil­lion (€250 mil­lion) to build out and ex­pand its vac­cine man­u­fac­tur­ing fa­cil­i­ties in Wavre, Bel­gium. The plant is ex­pect­ed to

23andMe re­ceived FDA clear­ance to re­port an ad­di­tion­al 41 vari­ants in the BR­CA1 and BR­CA2 genes, which are as­so­ci­at­ed with a high­er risk of breast,

The Stop TB Part­ner­ship an­nounced a 55% de­crease in the price for John­son & John­son’s ver­sion of be­daquiline known as Sir­turo, which is used to

Eu­roAPI will ac­quire Ger­man-based BianoGMP, a con­tract man­u­fac­tur­er of oligonu­cleotides, for €10 mil­lion, or $10.9 mil­lion. Found­ed in 2017, BianoGMP main­ly fo­cus­es on pro­duc­ing oligonu­cleotides

Ot­su­ka an­nounced plans to ac­quire Mind­set Phar­ma in a deal that po­si­tions the Japan­ese phar­ma in the psy­che­del­ic drug dis­cov­ery space. Ot­su­ka is pay­ing CAN

Charles Riv­er Lab­o­ra­to­ries plans to lay off 55 em­ploy­ees in the Bay Area af­ter de­cid­ing to stop its phar­ma­co­ki­net­ic and phar­ma­col­o­gy work there. Ac­cord­ing to

The FDA sent a warn­ing let­ter to Cal­i­for­nia-based eye drop man­u­fac­tur­er KC Phar­ma­ceu­ti­cals cit­ing sev­er­al is­sues re­lat­ed to the com­pa­ny’s qual­i­ty sys­tem. In the warn­ing

Sen. Raphael Warnock (D-GA) and eight oth­er Geor­gia law­mak­ers on Thurs­day asked the FDA for more trans­paren­cy over the short­age of can­cer drugs like cis­platin

Lif­era, the Sau­di Ara­bi­an-based con­tract man­u­fac­tur­er with back­ing from the na­tion’s Pub­lic In­vest­ment Fund, has part­nered with man­u­fac­tur­er Re­silience to es­tab­lish a pro­duc­tion site. Re­silience